Howard Mayer
Director/Board Member presso PEPGEN INC.
Profilo
Il dottor Howard Mayer, MD, è vicepresidente esecutivo di ricerca e sviluppo presso Ipsen SA, direttore indipendente presso Entasis Therapeutics Holdings, Inc. e vicepresidente esecutivo, responsabile della ricerca e sviluppo presso Ipsen Pharmaceuticals, Inc. Fa parte del consiglio di amministrazione di Adagio Therapeutics, Inc., Entasis Therapeutics Holdings, Inc. e Melmark Charitable Foundation. Il Dr. Mayer è stato precedentemente impiegato come direttore indipendente da Genocea Biosciences, Inc., come Chief Medical Officer, Senior VP, Head-R&D da Shire Plc, come Chief Medical Officer da EMD Serono, Inc., come Head-Clinical Development & Medical Affairs da Pfizer Inc., come Director-Infectious Diseases Clinical Research da Bristol Myers Squibb Co. e come Head-Rare Disease Business Unit, R&D da Takeda Pharmaceuticals U.S.A., Inc. È stato anche membro del consiglio di amministrazione di Autism Speaks, Inc. Ha conseguito la laurea presso l'Università della Pennsylvania e il dottorato presso l'Albert Einstein College of Medicine, Inc.
Posizioni attive di Howard Mayer
| Società | Posizione | Inizio |
|---|---|---|
| PEPGEN INC. | Director/Board Member | 15/11/2023 |
Melmark Charitable Foundation
 Melmark Charitable Foundation Investment Trusts/Mutual FundsMiscellaneous Melmark Charitable Foundation manages and coordinates all fundraising efforts throughout the Melmark organization. | Director/Board Member | 01/01/2016 |
Autism Speaks, Inc.
 Autism Speaks, Inc. Miscellaneous Commercial ServicesCommercial Services Autism Speaks, Inc. is an organization dedicated to advocating for individuals with autism spectrum disorder and their families. The non-profit company is based in New York, NY. The company aims to increase understanding and acceptance of people with autism and advance research into better interventions for autism spectrum disorder and related conditions. The company was founded by Robert C. Wright and Keith Andrew Wargo has been the CEO of the company since 2021. | Director/Board Member | 01/01/2011 |
Ipsen Pharmaceuticals, Inc.
 Ipsen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ipsen Pharmaceuticals, Inc. provides pharmaceutical products. The private company is based in Morristown, NJ. | Chief Tech/Sci/R&D Officer | 01/01/2019 |
Precedenti posizioni note di Howard Mayer
| Società | Posizione | Fine |
|---|---|---|
| IPSEN | Chief Tech/Sci/R&D Officer | 22/09/2023 |
| Ipsen Biopharmaceuticals, Inc. | Chief Tech/Sci/R&D Officer | 01/09/2023 |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Director/Board Member | 01/07/2022 |
| INVIVYD, INC. | Director/Board Member | 24/06/2022 |
| GENOCEA BIOSCIENCES, INC. | Director/Board Member | 03/08/2020 |
Formazione di Howard Mayer
| University of Pennsylvania | Undergraduate Degree |
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 6 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PFIZER, INC. | Health Technology |
| IPSEN | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| INVIVYD, INC. | Health Technology |
| PEPGEN INC. | Health Technology |
| Aziende private | 8 |
|---|---|
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Autism Speaks, Inc.
Autism Speaks, Inc. Miscellaneous Commercial ServicesCommercial Services Autism Speaks, Inc. is an organization dedicated to advocating for individuals with autism spectrum disorder and their families. The non-profit company is based in New York, NY. The company aims to increase understanding and acceptance of people with autism and advance research into better interventions for autism spectrum disorder and related conditions. The company was founded by Robert C. Wright and Keith Andrew Wargo has been the CEO of the company since 2021. | Commercial Services |
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Ipsen Pharmaceuticals, Inc.
Ipsen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ipsen Pharmaceuticals, Inc. provides pharmaceutical products. The private company is based in Morristown, NJ. | Health Technology |
| Ipsen Biopharmaceuticals, Inc. | |
Melmark Charitable Foundation
Melmark Charitable Foundation Investment Trusts/Mutual FundsMiscellaneous Melmark Charitable Foundation manages and coordinates all fundraising efforts throughout the Melmark organization. | Miscellaneous |
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- Howard Mayer
